有利风险前列腺癌患者中前列腺影像报告和数据系统3分病灶活检决策的实践层面差异
回顾密歇根泌尿外科质量改进协作组注册数据,纳入2013年1月至2020年3月接受MRI的3172例有利风险前列腺癌男性,其中473例为PI-RADS 3分病灶。发现不同泌尿外科实践间6个月无活检概率从28%到69%不等(中位59%),实践层面差异显著(P<0.001),而PI-RADS 3分至治疗的时间差异较小(P=0.2)。作者结论认为实践本身而非GG分级或活检阳性范围是影响活检决策的最大因素,需未来工作协助决策并减少差异。
要点
- 在有利风险前列腺癌考虑或接受主动监测的男性中,PI-RADS 3分病灶的活检率存在显著实践层面差异(P<0.001)。
- 6个月无活检概率在不同实践间从28%到69%不等(中位59%)。
- 从PI-RADS 3分到治疗的时间差异较小(P=0.2),年龄、PSA密度0.1-0.2、ISUP-GG 2及阳性针数与之有统计学显著关联。
核心结论
- 泌尿外科实践而非GG分级或活检阳性范围是影响有利风险前列腺癌考虑或接受主动监测男性中PI-RADS 3分病灶活检决策的最大因素。
- 需要未来工作协助决策并减少差异。
研究设计与样本
- 回顾密歇根泌尿外科质量改进协作组注册数据,纳入2013年1月至2020年3月接受MRI的有利风险前列腺癌男性(GG1和低体积GG2)。
- 共识别3172例接受MRI的有利风险前列腺癌男性,其中473例有PI-RADS 3分病灶。
- 主要结局为评估从MRI到活检及从MRI到治疗的时间的实践层面差异,包括诊断性活检后和主动监测期间获得的MRI。
- 采用Kaplan-Meier法估计从MRI到监测活检的无活检生存率,多变量Cox比例风险模型识别与发现PI-RADS 3分病灶后活检时间相关的临床和人口学因素。
主要发现
- PI-RADS 3分MRI结果患者中活检率存在显著实践层面差异(log-rank检验,P<0.001),6个月无活检概率从28%到69%不等(中位59%)。
- 未能识别与活检时间有显著关联的因素。
- 从PI-RADS 3分到治疗的时间差异较小(log-rank检验,P=0.2),而若干临床因素有统计学显著关联:年龄(P=0.018)、前列腺特异性抗原密度0.1-0.2(P=0.035)、ISUP-GG 2(P=0.002)及阳性针数(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine practice-level variation in the management of magnetic resonance imaging (MRI) Prostate Imaging-Reporting and Data System (PI-RADS) 3 lesions in men with favorable-risk prostate cancer (FRPC) considering or on active surveillance (AS). PATIENTS AND METHODS: We reviewed the Michigan Urological Surgery Improvement Collaborative registry for FRPC men (GG1 and low-volume GG2) undergoing MRI from January 2013 to March 2020. The primary outcome was to assess practice-level variation in time from MRI to biopsy and MRI to treatment for PI-RADS 3 lesions. Both MRIs obtained after the diagnostic biopsy and while on AS were included. The Kaplan-Meier method was used to estimate biopsy-free survival for time from MRI to surveillance biopsy and multivariable Cox proportional hazards models identified clinical and demographic factors associated with time obtaining a biopsy after finding PI-RADS 3 lesions. RESULTS: We identified 3172 FRPC men with a MRI, of whom 473 had a PI-RADS 3. There was significant practice-level variation in biopsy rates among patients with PI-RADS 3 MRI results (log-rank test, P <.001), with biopsy-free probability at 6 months ranging from 28% to 69% (median: 59%). We were unable to identify factors with significant associations with time to biopsy. Conversely, there was less variation in time from PI-RADS 3 to treatment (log-rank test, P = .2), while several clinical factors had statistically-significant associations: age (P = .018), Prostate Specific Antigen-Density 0.1-0.2 (P = .035), ISUP-GG 2 (P = .002), and number of positive cores (P <.001), as expected. CONCLUSION: Urology practice, rather than GG or extent of biopsy positivity, is the largest factor affecting the decision for biopsy of PI-RADS 3 lesions in FRPC men considering or on AS. Future work to assist with decision-making and reduce variability is needed.
引用
- Versalle D, Qi J, Noyes SL, et al. Practice-Level Variation in the Decision to Biopsy Prostate Imaging-Reporting and Data System 3 Lesions in Favorable-Risk Prostate Cancer Patients. Urology. 2022. PMID: 35081398. doi:10.1016/j.urology.2022.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。